Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer
The N-glycolylated ganglioside NeuGc-GM3 has been described in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but is usually not detected in normal human cells. Our aim was to evaluate the presence of NeuGc-GM3 in pediatric neuroectodermal tumors by immunohistochemis...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/245181 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558309061689344 |
|---|---|
| author | Alejandra M. Scursoni Laura Galluzzo Sandra Camarero Jessica Lopez Fabiana Lubieniecki Claudia Sampor Valeria I. Segatori Mariano R. Gabri Daniel F. Alonso Guillermo Chantada María Teresa G. de Dávila |
| author_facet | Alejandra M. Scursoni Laura Galluzzo Sandra Camarero Jessica Lopez Fabiana Lubieniecki Claudia Sampor Valeria I. Segatori Mariano R. Gabri Daniel F. Alonso Guillermo Chantada María Teresa G. de Dávila |
| author_sort | Alejandra M. Scursoni |
| collection | DOAJ |
| description | The N-glycolylated ganglioside NeuGc-GM3 has been described in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but is usually not detected in normal human cells. Our aim was to evaluate the presence of NeuGc-GM3 in pediatric neuroectodermal tumors by immunohistochemistry. Twenty-seven archival cases of neuroblastoma and Ewing sarcoma family of tumors (ESFT) were analyzed. Formalin-fixed, paraffin-embedded tumor samples were cut into 5 μm sections. The monoclonal antibody 14F7, a mouse IgG1 that specifically recognizes NeuGc-GM3, and a peroxidase-labeled polymer conjugated to secondary antibodies were used. Presence of NeuGc-GM3 was evident in 23 of 27 cases (85%), with an average of about 70% of positive tumors cells. Immunoreactivity was moderate to intense in most tumors, showing a diffuse cytoplasmic and membranous staining, although cases of ESFT demonstrated a fine granular cytoplasmic pattern. No significant differences were observed between neuroblastoma with and without NMYC oncogene amplification, suggesting that expression of NeuGc-GM3 is preserved in more aggressive cancers. Until now, the expression of N-glycolylated gangliosides in pediatric neuroectodermal tumors has not been investigated. The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors, suggesting its potential utility as a specific target of immunotherapy. |
| format | Article |
| id | doaj-art-419bb88c1b654ec0941352d0469db38a |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-419bb88c1b654ec0941352d0469db38a2025-02-03T01:32:40ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/245181245181Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric CancerAlejandra M. Scursoni0Laura Galluzzo1Sandra Camarero2Jessica Lopez3Fabiana Lubieniecki4Claudia Sampor5Valeria I. Segatori6Mariano R. Gabri7Daniel F. Alonso8Guillermo Chantada9María Teresa G. de Dávila10Departament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartment of Hemato-Oncology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaLaboratory of Molecular Oncology, Quilmes National University, B1876BXD Buenos Aires, ArgentinaLaboratory of Molecular Oncology, Quilmes National University, B1876BXD Buenos Aires, ArgentinaLaboratory of Molecular Oncology, Quilmes National University, B1876BXD Buenos Aires, ArgentinaDepartment of Hemato-Oncology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaDepartament of Pathology, Pediatric Hospital “Prof. Dr. Juan P. Garrahan”, C1245AAM Buenos Aires, ArgentinaThe N-glycolylated ganglioside NeuGc-GM3 has been described in solid tumors such as breast carcinoma, nonsmall cell lung cancer, and melanoma, but is usually not detected in normal human cells. Our aim was to evaluate the presence of NeuGc-GM3 in pediatric neuroectodermal tumors by immunohistochemistry. Twenty-seven archival cases of neuroblastoma and Ewing sarcoma family of tumors (ESFT) were analyzed. Formalin-fixed, paraffin-embedded tumor samples were cut into 5 μm sections. The monoclonal antibody 14F7, a mouse IgG1 that specifically recognizes NeuGc-GM3, and a peroxidase-labeled polymer conjugated to secondary antibodies were used. Presence of NeuGc-GM3 was evident in 23 of 27 cases (85%), with an average of about 70% of positive tumors cells. Immunoreactivity was moderate to intense in most tumors, showing a diffuse cytoplasmic and membranous staining, although cases of ESFT demonstrated a fine granular cytoplasmic pattern. No significant differences were observed between neuroblastoma with and without NMYC oncogene amplification, suggesting that expression of NeuGc-GM3 is preserved in more aggressive cancers. Until now, the expression of N-glycolylated gangliosides in pediatric neuroectodermal tumors has not been investigated. The present study evidenced the expression of NeuGc-GM3 in a high proportion of neuroectodermal tumors, suggesting its potential utility as a specific target of immunotherapy.http://dx.doi.org/10.1155/2011/245181 |
| spellingShingle | Alejandra M. Scursoni Laura Galluzzo Sandra Camarero Jessica Lopez Fabiana Lubieniecki Claudia Sampor Valeria I. Segatori Mariano R. Gabri Daniel F. Alonso Guillermo Chantada María Teresa G. de Dávila Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer Clinical and Developmental Immunology |
| title | Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer |
| title_full | Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer |
| title_fullStr | Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer |
| title_full_unstemmed | Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer |
| title_short | Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer |
| title_sort | detection of n glycolyl gm3 ganglioside in neuroectodermal tumors by immunohistochemistry an attractive vaccine target for aggressive pediatric cancer |
| url | http://dx.doi.org/10.1155/2011/245181 |
| work_keys_str_mv | AT alejandramscursoni detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT lauragalluzzo detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT sandracamarero detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT jessicalopez detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT fabianalubieniecki detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT claudiasampor detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT valeriaisegatori detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT marianorgabri detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT danielfalonso detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT guillermochantada detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer AT mariateresagdedavila detectionofnglycolylgm3gangliosideinneuroectodermaltumorsbyimmunohistochemistryanattractivevaccinetargetforaggressivepediatriccancer |